Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1060 - Metabolic Syndrome in Luminal-Type Non-Metastatic Breast Cancer during Hormonal Treatment Does it really have impact on prognosis?

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Kartika Taroeno-Hariadi

Citation

Annals of Oncology (2018) 29 (suppl_9): ix8-ix12. 10.1093/annonc/mdy427

Authors

K.W. Taroeno-Hariadi1, M.S. Hardianti1, J. Kurnianda1, Y.R. Putra2, T. Aryandono3

Author affiliations

  • 1 Internal Medicine Hemato-medical Oncology, Gadjah Mada University/Dr. Sardjito General Hospital, 55281 - Yogyakarta/ID
  • 2 Internal Medicine, Gadjah Mada University/Dr. Sardjito General Hospital, 55281 - Yogyakarta/ID
  • 3 Surgical Oncology, Gadjah Mada University/Dr. Sardjito General Hospital, 55281 - yogyakarta/ID
More

Resources

Abstract 1060

Background

Metabolic Syndrome (MetS) has been shown as risk and prognostic factors of cancer. MetS affects the prognosis of breast cancer patients differently according to the race, breast cancer type, metabolic component, cancer treatment and concomitant medication. Whether MetS influence the prognosis of the luminal type breast cancer patients has not been confirmed yet. This study aims at analyzing the association between metabolic syndrome and disease-free survival of luminal-type breast cancer patients.

Methods

Data from medical record of all non-metastatic breast cancer patients, luminal-type, HER-2 negative, receiving chemotherapy ± radiotherapy and or hormonal therapy, and diagnosed between 2013 – 2018 were extracted and included for this retrospective study. Cases with previous or concomitant malignancy, or which recurrent event is not assessed by imaging or cytology, or incomplete data, or follow up cannot be done were excluded from study. MetS is defined as Modified NCEP ATP III for Asian. Kaplan-Meir Survival analysis were used to estimate cumulative survival time for recurrence based on MetS status of breast cancer patients.

Results

There were 127 non-metastatic, luminal-type breast cancer included for analysis. Median age of subjects was 54-year-old (36-84 years). MetS were found in 47.2% of breast cancer patients with luminal type. Obesity and overweight occured in 40.9%; hypertension in 50.4%; low LDL in 51.2%; hyperglycemia in 56.7%; and increased waist circumference in 56.7%. Relapsed rate was similar between MetS and metabolic normal patients. Eighteen out of 60 luminal-type breast cancer patients with MetS were recurred (30%) as well as 33.3% of breast cancer without MetS. Median disease-free survival in MetS luminal type breast cancer was 84 months while in non MetS was 106 months (95% CI 16,6-151.3; p < 0.62).

Conclusions

In luminal-type breast cancer patients, MetS was not a prognostic factor for relapse. Concomitant medications used for metabolic syndromes, or cancer treatment may obscure the results.

Editorial acknowledgement

Clinical trial identification

Ethics Committee Approval KE/FK/0670/EC/2018.

Legal entity responsible for the study

Medical And Health Research Ethics Commitee (MHREC) Faculty of Medicine Gadjah Mada University - Dr Sardjito Hospital.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings